Novo Nordisk Wrestles $25 Million Ransomware Demand as It Expands Plants in Three Countries and Oral Wegovy Gains Traction
18.06.2026 - 21:07:12 | boerse-global.de
Novo Nordisk finds itself squeezed between two powerful forces: an aggressive global manufacturing buildout and a cybersecurity crisis that has dumped 1.3 terabytes of sensitive corporate data into the hands of hackers. The Danish pharmaceutical giant has confirmed that the ransomware group FulcrumSec breached its internal IT systems, copying pseudonymized clinical trial documents, source code, 30 trained AI models, and nearly 500 gigabytes of microscopy images. The attackers are demanding $25 million and threatening public release, but Novo Nordisk has so far refused to pay. The company stressed that direct patient identifiers were not compromised, and that both operations and supply chains remain fully intact—a claim the markets are watching closely.
The breach, discovered on June 11, is believed by analysts to have originated from exposed credentials that gave the intruders access to development environments. While the security incident dominates headlines, Novo Nordisk is simultaneously pouring capital into production capacity on three continents. In China, it is investing roughly 200 million CNY—around $30 million—into expanding its Tianjin facility, which channels 60% of its output to the domestic market and 40% to exports. That plant has been a cornerstone of Novo Nordisk’s presence in the country since 2003, with total investments now exceeding 17 billion CNY; more than 6 billion CNY has been deployed since 2023 alone. Across Europe, close to $380 million is flowing into a new production site in Bohumil, Czech Republic, while Ireland’s Athlone plant is getting a €432 million upgrade scheduled for completion by 2028. These investments are designed to fortify the supply chain for GLP-1 drugs and insulin products, with the Chinese site also launching NovoJie—a once-weekly combination of basal insulin and a GLP-1 receptor agonist that the company calls a global first.
Parallel to the factory expansions, Novo Nordisk has been deepening its pipeline through high-stakes partnerships. A deal worth up to $2.1 billion with Boston-based Vivtex brings the GI-ORIS platform to improve oral delivery of biologics—a critical weapon in the arms race against Eli Lilly. Separately, a collaboration with Replicate Bioscience targets self-replicating RNA therapies for metabolic diseases, with potential milestone payments of $550 million.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the commercial front, the oral version of Wegovy is proving a standout performer. Launched in the United States on January 5, it had racked up more than 3 million prescriptions within just 22 weeks. By May, one-third of all Wegovy prescriptions were for the pill form, and among new patients the share rose to 40%. Over 80% of those new users had never taken a GLP-1 therapy before. In the UK, the MHRA approved the 25 mg semaglutide tablet on June 11, backed by the OASIS-4 study showing a 13.6% weight loss versus 2.4% in the placebo group over 64 weeks. CEO Mike Doustdar has confirmed that a Chinese approval application will be filed in the coming months, aiming to beat Eli Lilly’s own oral contender to market. Berenberg responded to the momentum by lifting its price target to 325 DKK (roughly €43.50) and reiterating a buy rating.
Despite these bright spots, the stock remains under heavy pressure. Shares hover near €37.80, having shed around 42% from the 52-week high of €65.20 recorded last June. The year-to-date decline stands at roughly 16%. A modest technical reprieve comes from the 50-day moving average of about €36.85, which is providing short-term support, while the RSI of 50 to 53 signals neutral territory—neither oversold nor overbought. Novo Nordisk is leaning on a 15 billion DKK buyback program to steady the ship; more than 5 billion DKK has already been deployed.
The weeks ahead will test whether the company’s commercial and manufacturing firepower can outweigh the reputational and financial drag of the cyberattack. How Novo Nordisk manages the narrative—and whether FulcrumSec follows through on its threat—will likely shape the stock’s trajectory as much as any new prescription data or factory groundbreaking.
Ad
Novo Nordisk Stock: New Analysis - 18 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
